| 000 | 01153 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250517154549.0 | ||
| 264 | 0 | _c20181030 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.00258-17 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAnthony, R M | |
| 245 | 0 | 0 |
_aProtecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _c06 2017 |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAmidohydrolases _xgenetics |
| 650 | 0 | 4 | _aAntitubercular Agents |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aMycobacterium tuberculosis |
| 650 | 0 | 4 | _aPyrazinamide |
| 650 | 0 | 4 | _aTuberculosis, Multidrug-Resistant |
| 700 | 1 | _aCynamon, M | |
| 700 | 1 | _aHoffner, S | |
| 700 | 1 | _aWerngren, J | |
| 700 | 1 | _aden Hertog, A L | |
| 700 | 1 | _avan Soolingen, D | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 61 _gno. 6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.00258-17 _zAvailable from publisher's website |
| 999 |
_c27205518 _d27205518 |
||